A Phase II Study of Merbarone in Patients with Adenocarcinoma of the Pancreas
作者:
JonesDennie V.,
AjaniJaffer A.,
WinnRodger J.,
DaughertyKaren R.,
LevinBernard,
KrakoffIrwin H.,
期刊:
Cancer Investigation
(Taylor Available online 1993)
卷期:
Volume 11,
issue 6
页码: 667-669
ISSN:0735-7907
年代: 1993
DOI:10.3109/07357909309046939
出版商: Taylor&Francis
数据来源: Taylor
摘要:
Merbarone, a nonsedating derivative of thiobarbituric acid that has demonstrated antineoplastic activity against a variety of murine tumors, was evaluated in a phase II trial in patients with advanced, measurable adenocarcinoma of the pancreas. Seventeen patients were treated at a starting dose of 1000 mglnflday for 5 days by continuous intravenous infusion; the dose was escalated in accordance with the toxicity experienced, and no dosage reductions owing to toxicity were required. No complete or partial responses were observed, and only one minor response was documented, suggesting that merbarone is ineffective against pancreatic cancer at the doses and schedule in which it was administered in this trial.
点击下载:
PDF (219KB)
返 回